With 1.69 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.27 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $0.1587 whereas the lowest price it dropped to was $0.1356. The 52-week range on HUGE shows that it touched its highest point at $1.68 and its lowest point at $0.13 during that stretch. It currently has a 1-year price target of $2.60. Beta for the stock currently stands at 0.59.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HUGE was up-trending over the past week, with a rise of 2.84%, but this was down by -10.99% over a month. Three-month performance dropped to -68.88% while six-month performance fell -81.44%. The stock lost -86.77% in the past year, while it has lost -83.45% so far this year. A look at the trailing 12-month EPS for HUGE yields -0.26 with Next year EPS estimates of -0.12. For the next quarter, that number is -0.06. This implies an EPS growth rate of 52.17% for this year and 45.45% for next year.
Float and Shares Shorts:
At present, 39.38 million HUGE shares are outstanding with a float of 34.63 million shares on hand for trading. On 2024-06-28, short shares totaled 98469.0, which was 21.0 higher than short shares on 1717113600. In addition to Mr. Zeeshan Saeed as the firm’s Founder, CEO, President & Executive Co-Chairman, Mr. Anthony John Durkacz serves as its Founder & Executive Co-Chairman.
Institutional Ownership:
Through their ownership of 0.02853 of HUGE’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-03-31, HUGE reported revenue of $0.0 and operating income of -$2253213.0. The EBITDA in the recently reported quarter was -$1960548.0 and diluted EPS was -$0.05.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HUGE since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
